	US 12,173,038 B2
	High affinity anticalins directed against human CD98hc
Arne Skerra, Dachau (DE); Friedrich-Christian Deuschle, Freising (DE); André Schiefner, Nuremberg (DE); and Volker Morath, Munich (DE)
Assigned to TECHNISCHE UNIVERSITÄT MÜNCHEN, Munich (DE)
Appl. No. 17/440,520
Filed by Technische Universität München, Munich (DE)
PCT Filed Mar. 18, 2020, PCT No. PCT/EP2020/057469 § 371(c)(1), (2) Date Sep. 17, 2021, PCT Pub. No. WO2020/193316, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 19165966 (EP), filed on Mar. 28, 2019.
Prior Publication US 2022/0153790 A1, May 19, 2022
Int. Cl. A61K 38/16 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 38/00 (2013.01); C07K 2319/00 (2013.01)]

11 Claims

1. A cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein, wherein the CD98hc-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein, and wherein the CD98hc-specific binding protein

(a) comprises or consists of an amino acid sequence as represented in formula I:

QDSTSD(X₁)(X₂)PAPPLSKVPLQQNFQDNQF(Q/H)GKWY(X₃)VG

(X₄)AG(X₅)(X₆)(X₇)(X₈)(X₉)E(X₁₀)(X₁₁)(X₁₂)(X₁₃)

(X₁₄)(X₁₅)M(X₁₆)ATIYELKEDKS(Y/F)NVT(X₁₇)V(X₁₈)

(X₁₉)(X₂₀)(X₂₁)(K/T)KC(X₂₂)(Y/N)(X₂₃)(X₂₄)(X₂₅)

(T/S)(X₂₆)VPG(C/S)QPGE(F/Y)(T/N)(X₂₇)G(N/K)I(X₂₈)

S(Y/R/G/A)P(X₂₉)(X₃₀)(X₃₁)S(X₃₂)L(X₃₃)RVVSTNYNQ

(H/Y)A(M/L)VF(X₃₄)K(X₃₅)(V/E)(X₃₆)(X₃₇)N(X₃₈)E

(X₃₉)(X₄₀)(X₄₁)I(X₄₂)L(X₄₃)GRTKELTSELKE(N/I/Y)FIR

FSKSLGLPE(X₄₄)(X₄₅)IVFPVPIDQCIDG,

wherein

(X₁) is L;

(X₂) is I;

(X₃) is V;

(X₄) is R;

(X₅) is N;

(X₆) is L or T;

(X₇) is G;

(X₈) is L;

(X₉) is R;

(X₁₀) is D;

(X₁₁) is K;

(X₁₂) is D;

(X₁₃) is P;

(X₁₄) is A or G;

(X₁₅) is K;

(X₁₆) is F;

(X₁₇) is Y;

(X₁₈) is W;

(X₁₉) is F or S;

(X₂₀) is D or G;

(X₂₁) is L or Q;

(X₂₂) is K or M;

(X₂₃) is S;

(X₂₄) is I;

(X₂₅) is H, G or V;

(X₂₆) is F;

(X₂₇) is L;

(X₂₈) is K;

(X₂₉) is G;

(X₃₀) is H, R or Q;

(X₃₁) is T;

(X₃₂) is W;

(X₃₃) is V;

(X₃₄) is F;

(X₃₅) is W or S;

(X₃₆) is G or T;

(X₃₇) is Q;

(X₃₈) is R;

(X₃₉) is N, G or E;

(X₄₀) is F;

(X₄₁) is A;

(X₄₂) is T;

(X₄₃) is Y;

(X₄₄) is N; and

(X₄₅) is H; or

(b) comprises or consists of an amino acid sequence which is at least 80% identical to the amino acid sequence of (a), provided that amino acid positions (X₁) to (X₄₅) are maintained as defined in item (a).